|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| Cash | ||||||||||||||||||||
| Interest-bearing deposits in other financial institutions | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Available-for-sale securities | ||||||||||||||||||||
| Held-to-maturity securities | ||||||||||||||||||||
| Mortgage loans held for sale | ||||||||||||||||||||
| Loans receivable, net of allowance for credit losses of $63,965 - June 2026; $64,771 - December 2025 | ||||||||||||||||||||
| Interest receivable | ||||||||||||||||||||
| Prepaid expenses and other assets | ||||||||||||||||||||
| Other real estate owned and repossessions, net | ||||||||||||||||||||
| Premises and equipment, net | ||||||||||||||||||||
| Goodwill and other intangible assets | ||||||||||||||||||||
| Federal Home Loan Bank stock and other interest-earning assets | ||||||||||||||||||||
| Current and deferred income taxes | ||||||||||||||||||||
| Total Assets | ||||||||||||||||||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||||||||||||||
| Liabilities: | ||||||||||||||||||||
| Deposits | ||||||||||||||||||||
| Securities sold under reverse repurchase agreements with customers | ||||||||||||||||||||
| Short-term borrowings and other interest-bearing liabilities | ||||||||||||||||||||
| Subordinated debentures issued to capital trust | ||||||||||||||||||||
| Subordinated notes | ||||||||||||||||||||
| Accrued interest payable | ||||||||||||||||||||
| Advances from borrowers for taxes and insurance | ||||||||||||||||||||
| Accrued expenses and other liabilities | ||||||||||||||||||||
| Accounts payable and accrued expenses | ||||||||||||||||||||
| Liability for unfunded commitments | ||||||||||||||||||||
| Total Liabilities | ||||||||||||||||||||
| Stockholders' Equity: | ||||||||||||||||||||
| Preferred stock, $.01 par value; authorized 1,000,000 shares; issued and outstanding June 2026 and December 2025 - - 0 - shares | ||||||||||||||||||||
| Common stock, $.01 par value; authorized 20,000,000 shares; issued and outstanding June 2026 - 10,884,444 shares; December 2025 - 11,062,252 shares | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Total Stockholders' Equity | ||||||||||||||||||||
| Total Liabilities and Stockholders' Equity |
Loading...
